ALTERITY THERAPEUTICS-ADR (ATHE) Stock Overview
USA - NASDAQ:ATHE - US02155X2053 - ADR
ATHE Key Statistics, Chart & Performance
The current stock price of ATHE is 4.48 USD. In the past month the price decreased by -9.49%. In the past year, price increased by 264.23%.
ATHE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.01 | 393.01B | ||
| AMGN | AMGEN INC | 13.09 | 153.65B | ||
| GILD | GILEAD SCIENCES INC | 14.74 | 141.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.62 | 98.23B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.97 | 62.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.45B | ||
| ARGX | ARGENX SE - ADR | 79.48 | 45.09B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.84 | 39.75B | ||
| INSM | INSMED INC | N/A | 30.60B | ||
| NTRA | NATERA INC | N/A | 24.86B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.13B | ||
| BIIB | BIOGEN INC | 8.9 | 20.89B |
Related stock screener links
About ATHE
Company Profile
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Company Info
ALTERITY THERAPEUTICS-ADR
L 3 460 Bourke St
Melbourne VICTORIA VIC 3000 AU
CEO: David A. Stamler
Employees: 10
Phone: 61393494906
ALTERITY THERAPEUTICS-ADR / ATHE FAQ
What is the stock price of ALTERITY THERAPEUTICS-ADR today?
The current stock price of ATHE is 4.48 USD. The price increased by 2.28% in the last trading session.
What is the ticker symbol for ALTERITY THERAPEUTICS-ADR stock?
The exchange symbol of ALTERITY THERAPEUTICS-ADR is ATHE and it is listed on the Nasdaq exchange.
On which exchange is ATHE stock listed?
ATHE stock is listed on the Nasdaq exchange.
What is ALTERITY THERAPEUTICS-ADR worth?
ALTERITY THERAPEUTICS-ADR (ATHE) has a market capitalization of 66.32M USD. This makes ATHE a Micro Cap stock.
How many employees does ALTERITY THERAPEUTICS-ADR have?
ALTERITY THERAPEUTICS-ADR (ATHE) currently has 10 employees.
What are the support and resistance levels for ALTERITY THERAPEUTICS-ADR (ATHE) stock?
ALTERITY THERAPEUTICS-ADR (ATHE) has a support level at 4.38 and a resistance level at 5. Check the full technical report for a detailed analysis of ATHE support and resistance levels.
Is ALTERITY THERAPEUTICS-ADR (ATHE) expected to grow?
The Revenue of ALTERITY THERAPEUTICS-ADR (ATHE) is expected to grow by 1291.8% in the next year. Check the estimates tab for more information on the ATHE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ALTERITY THERAPEUTICS-ADR (ATHE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ATHE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ATHE, evaluating the profitability, health, valuation and growth aspects
- ALTERITY THERAPEUTICS-ADR (ATHE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALTERITY THERAPEUTICS-ADR (ATHE) Sales and EPS estimates to see what analysts future expectations are.
- ALTERITY THERAPEUTICS-ADR (ATHE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALTERITY THERAPEUTICS-ADR (ATHE) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALTERITY THERAPEUTICS-ADR (ATHE) Stock Chart to make your own analysis
- ALTERITY THERAPEUTICS-ADR (ATHE) Latest news and press-releases to stay up to date.
Does ALTERITY THERAPEUTICS-ADR (ATHE) stock pay dividends?
ATHE does not pay a dividend.
When does ALTERITY THERAPEUTICS-ADR (ATHE) report earnings?
ALTERITY THERAPEUTICS-ADR (ATHE) will report earnings on 2026-02-26.
What is the Price/Earnings (PE) ratio of ALTERITY THERAPEUTICS-ADR (ATHE)?
ALTERITY THERAPEUTICS-ADR (ATHE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.72).
What is the Short Interest ratio of ALTERITY THERAPEUTICS-ADR (ATHE) stock?
The outstanding short interest for ALTERITY THERAPEUTICS-ADR (ATHE) is 0.65% of its float. Check the ownership tab for more information on the ATHE short interest.
ATHE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ATHE. When comparing the yearly performance of all stocks, ATHE is one of the better performing stocks in the market, outperforming 97.31% of all stocks.
ATHE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ATHE. ATHE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ATHE Financial Highlights
Over the last trailing twelve months ATHE reported a non-GAAP Earnings per Share(EPS) of -0.72. The EPS increased by 59.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.39% | ||
| ROE | -28.65% | ||
| Debt/Equity | 0 |
ATHE Forecast & Estimates
For the next year, analysts expect an EPS growth of 100% and a revenue growth 1291.8% for ATHE